CYCLONE3
12 Apr 2022
Trial Summary
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse.
Acronym:
CYCLONE 3
ACTRN/NCT /ethics:
NCT05288166
Scientific title:
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Sponsor / Cooperative group:
Eli Lilly and Company
Trial & Patient Characteristics
| Cancer Type | Prostate |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Male |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2022-04-01 |
| Anticipated End Date | 2027-10-01 |
Participating Hospitals
| Hospital | Icon Cancer Centre Adelaide |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| sue.yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dr Anas Alawawdeh |
| Recruitment Status | Recruiting |
| Hospital | Lyell McEwin Hospital |
|---|---|
| Clinical Trial Coordinator | Andy Phay |
| andy.phay@sa.gov.au | |
| Phone | 08 8282 0833 |
| Principal Investigator | Dr Christopher Hocking |
| Recruitment Status | Recruiting |